Litcius/Paper detail

Preclinical Gold Complexes as Oral Drug Candidates to Treat Leishmaniasis Are Potent Trypanothione Reductase Inhibitors

Luiza Guimarães Tunes, Roberta E. Morato, Adriana García, Vinicius Schmitz, Mário Steindel, José Dias Corrêa, Hélio F. Dos Santos, Fréderic Frézard, Mauro V. de Almeida, Heveline Silva, Nilmar Silvio Moretti, André Luís Branco de Barros, Rubens Lima do Monte‐Neto

2020ACS Infectious Diseases57 citationsDOIOpen Access PDF

Abstract

presented favorable pharmacokinetic and toxicity profiles that encourage further drug development studies. Gold(I) complexes are promising antileishmanial agents, with a potential for therapeutic use, including in leishmaniasis caused by antimony-resistant parasites.

Topics & Concepts

MiltefosinePharmacologyAmastigoteReactive oxygen speciesChemistryLeishmaniasisLeishmaniaBiologyMicrobiologyBiochemistryImmunologyParasite hostingVisceral leishmaniasisComputer scienceWorld Wide WebResearch on Leishmaniasis StudiesTrypanosoma species research and implicationsParasites and Host Interactions
Preclinical Gold Complexes as Oral Drug Candidates to Treat Leishmaniasis Are Potent Trypanothione Reductase Inhibitors | Litcius